Not Yet RecruitingPhase 3

Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

China550 participantsStarted 2025-08-01

Plain-language summary

This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Newly diagnosed, histologically confirmed non-keratinizing carcinoma (WHO classification).
✓. Stage I-III disease (AJCC 9th edition).
✓. Tumor extends to nasal cavity (including nasal septum).
✓. No distant metastasis (M0).
✓. Age 18-70 years.
✓. Male or non-pregnant female.
✓. Scheduled for radiotherapy.
✓. ECOG performance status 0-1 .

Exclusion criteria

✕. Keratinizing squamous cell carcinoma (WHO Type I) or basaloid squamous cell carcinoma.
✕. Age \<18 or \>70 years.
✕. Recurrent disease or distant metastasis.
✕. No tumor extension into the nasal cavity (including the nasal septum).
✕. Prior malignancy (except adequately treated basal/squamous cell skin cancer or cervical carcinoma in situ).
✕. Pregnancy/lactation (premenopausal women require pregnancy test; effective contraception mandated).
✕

What they're measuring

Local relapse-free survival

Timeframe: 3 year

Trial details

NCT IDNCT07072000

SponsorHai-Qiang Mai,MD,PhD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-07-31

Contact for this trial

Hai-Qiang Mai, Dr.

+8602087343380 maihq@sysucc.org.cn

View on ClinicalTrials.gov More Nasopharyngeal Cancinoma (NPC) trials